Is lanreotide and/or interferon alfa an adequate therapy for neuroendocrine tumors?

J Clin Oncol. 2004 Feb 1;22(3):573; author reply 574-5. doi: 10.1200/JCO.2004.99.175.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Clinical Trials as Topic
  • Gastrointestinal Neoplasms / drug therapy*
  • Gastrointestinal Neoplasms / pathology
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Neuroendocrine Tumors / drug therapy*
  • Neuroendocrine Tumors / secondary
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / pathology
  • Peptides, Cyclic / administration & dosage
  • Recombinant Proteins
  • Somatostatin / administration & dosage
  • Somatostatin / analogs & derivatives*

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Peptides, Cyclic
  • Recombinant Proteins
  • lanreotide
  • Somatostatin